425 related articles for article (PubMed ID: 12480191)
1. Challenging the platinum combinations in the chemotherapy of NSCLC.
Douillard JY; Eckardt J; Scagliotti GV
Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
[TBL] [Abstract][Full Text] [Related]
2. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Rigas JR
Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
[TBL] [Abstract][Full Text] [Related]
3. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
5. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
[TBL] [Abstract][Full Text] [Related]
7. [Developed new agents for lung cancer].
Kato Y; Saijo N
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
[TBL] [Abstract][Full Text] [Related]
8. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Green MR
Semin Oncol; 2002 Jun; 29(3 Suppl 12):17-21. PubMed ID: 12170447
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
10. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Mavroudis D
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
[No Abstract] [Full Text] [Related]
13. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
16. [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Hosomi Y; Shibuya M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):527-32. PubMed ID: 17431336
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Ornstein DL; Nervi AM; Rigas JR
Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]